We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Pfizer Inc | NYSE:PFE | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.16 | 0.58% | 27.86 | 27.905 | 27.52 | 27.86 | 60,567,753 | 00:59:06 |
From May 2019 to May 2024
By Michael Dabaie
OPKO Health Inc. (OPK) shares were up 12%, to $2.34, in premarket trading Monday.
OPKO and Pfizer Inc. (PFE) said the Phase 3 trial evaluating somatrogon dosed once-weekly in pre-pubertal children with growth-hormone deficiency met its primary endpoint of non-inferiority to daily Genotropin for injection, as measured by annual height velocity at 12 months.
The results demonstrated the potential to reduce current dosing frequency from once-daily to a single weekly injection, the companies said.
In 2014, Pfizer and OPKO entered into a worldwide agreement for the development and commercialization of somatrogon for the treatment of GHD. OPKO is responsible for conducting the clinical program and Pfizer is responsible for registering and commercializing the product.
Pfizer shares were up 0.6% premarket, to $36.66.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
October 21, 2019 08:44 ET (12:44 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Pfizer Chart |
1 Month Pfizer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
